117 related articles for article (PubMed ID: 38266814)
21. Cytotoxic T lymphocytes elicited by dendritic cell-targeted delivery of human papillomavirus type-16 E6/E7 fusion gene exert lethal effects on CaSki cells.
Wu XM; Liu X; Jiao QF; Fu SY; Bu YQ; Song FZ; Yi FP
Asian Pac J Cancer Prev; 2014; 15(6):2447-51. PubMed ID: 24761845
[TBL] [Abstract][Full Text] [Related]
22. Anti-viral Effects of Superpositively Charged Mutant of Green Fluorescent Protein.
Vahabpour R; Basimi P; Roohvand F; Asadi H; Irani GM; Zabihollahi R; Bolhassani A
Protein Pept Lett; 2019; 26(12):930-939. PubMed ID: 31441722
[TBL] [Abstract][Full Text] [Related]
23. Long-term protection against human papillomavirus e7-positive tumor by a single vaccination of adeno-associated virus vectors encoding a fusion protein of inactivated e7 of human papillomavirus 16/18 and heat shock protein 70.
Zhou L; Zhu T; Ye X; Yang L; Wang B; Liang X; Lu L; Tsao YP; Chen SL; Li J; Xiao X
Hum Gene Ther; 2010 Jan; 21(1):109-19. PubMed ID: 19715402
[TBL] [Abstract][Full Text] [Related]
24. Fungal mannosylation enhances human papillomavirus 16 E7 therapeutic immunity against TC-1 tumors.
Wang Z; Wei C; Zhang Y; Wang W; Zhou Z; Xiao G
Oncol Rep; 2018 Jan; 39(1):425-432. PubMed ID: 29115562
[TBL] [Abstract][Full Text] [Related]
25. A Chlamydomonas-derived Human Papillomavirus 16 E7 vaccine induces specific tumor protection.
Demurtas OC; Massa S; Ferrante P; Venuti A; Franconi R; Giuliano G
PLoS One; 2013; 8(4):e61473. PubMed ID: 23626690
[TBL] [Abstract][Full Text] [Related]
26. Fusion protein vaccines targeting two tumor antigens generate synergistic anti-tumor effects.
Cheng WF; Chang MC; Sun WZ; Jen YW; Liao CW; Chen YY; Chen CA
PLoS One; 2013; 8(9):e71216. PubMed ID: 24058440
[TBL] [Abstract][Full Text] [Related]
27. GTL001 and bivalent CyaA-based therapeutic vaccine strategies against human papillomavirus and other tumor-associated antigens induce effector and memory T-cell responses that inhibit tumor growth.
Esquerré M; Momot M; Goubier A; Gonindard C; Leung-Theung-Long S; Misseri Y; Bissery MC
Vaccine; 2017 Mar; 35(11):1509-1516. PubMed ID: 28196735
[TBL] [Abstract][Full Text] [Related]
28. A Therapeutic DNA Vaccine Targeting HPV16 E7 in Combination with Anti-PD-1/PD-L1 Enhanced Tumor Regression and Cytotoxic Immune Responses.
Han X; Gao Z; Cheng Y; Wu S; Chen J; Zhang W
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895145
[TBL] [Abstract][Full Text] [Related]
29. Engineered outer membrane vesicle is potent to elicit HPV16E7-specific cellular immunity in a mouse model of TC-1 graft tumor.
Wang S; Huang W; Li K; Yao Y; Yang X; Bai H; Sun W; Liu C; Ma Y
Int J Nanomedicine; 2017; 12():6813-6825. PubMed ID: 28979120
[TBL] [Abstract][Full Text] [Related]
30. A novel fusion protein-based vaccine comprising a cell penetrating and immunostimulatory peptide linked to human papillomavirus (HPV) type 16 E7 antigen generates potent immunologic and anti-tumor responses in mice.
Granadillo M; Vallespi MG; Batte A; Mendoza O; Soria Y; Lugo VM; Torrens I
Vaccine; 2011 Jan; 29(5):920-30. PubMed ID: 21145912
[TBL] [Abstract][Full Text] [Related]
31. Oral immunization with a Lactobacillus casei vaccine expressing human papillomavirus (HPV) type 16 E7 is an effective strategy to induce mucosal cytotoxic lymphocytes against HPV16 E7.
Adachi K; Kawana K; Yokoyama T; Fujii T; Tomio A; Miura S; Tomio K; Kojima S; Oda K; Sewaki T; Yasugi T; Kozuma S; Taketani Y
Vaccine; 2010 Apr; 28(16):2810-7. PubMed ID: 20170766
[TBL] [Abstract][Full Text] [Related]
32. Small heat shock protein 27: An effective adjuvant for enhancement of HIV-1 Nef antigen-specific immunity.
Milani A; Bolhassani A; Shahbazi S; Motevalli F; Sadat SM; Soleymani S
Immunol Lett; 2017 Nov; 191():16-22. PubMed ID: 28917624
[TBL] [Abstract][Full Text] [Related]
33. Prophylactic and therapeutic efficacy of an attenuated Listeria monocytogenes-based vaccine delivering HPV16 E7 in a mouse model.
Jia Y; Yin Y; Duan F; Fu H; Hu M; Gao Y; Pan Z; Jiao X
Int J Mol Med; 2012 Dec; 30(6):1335-42. PubMed ID: 23027427
[TBL] [Abstract][Full Text] [Related]
34. A Genetically Modified attenuated
Jia YY; Tan WJ; Duan FF; Pan ZM; Chen X; Yin YL; Jiao XA
Front Cell Infect Microbiol; 2017; 7():279. PubMed ID: 28706878
[TBL] [Abstract][Full Text] [Related]
35. A novel self-assembled nanoparticle vaccine with HIV-1 Tat₄₉₋₅₇/HPV16 E7₄₉₋₅₇ fusion peptide and GM-CSF DNA elicits potent and prolonged CD8⁺ T cell-dependent anti-tumor immunity in mice.
Tang J; Yin R; Tian Y; Huang Z; Shi J; Fu X; Wang L; Wu Y; Hao F; Ni B
Vaccine; 2012 Feb; 30(6):1071-82. PubMed ID: 22178528
[TBL] [Abstract][Full Text] [Related]
36. Oral immunization with recombinant Lactococcus lactis NZ9000 expressing human papillomavirus type 16 E7 antigen and evaluation of its immune effects in female C57BL/6 mice.
Mohseni AH; Razavilar V; Keyvani H; Razavi MR; Khavari-Nejad RA
J Med Virol; 2019 Feb; 91(2):296-307. PubMed ID: 30192395
[TBL] [Abstract][Full Text] [Related]
37. DNA vaccines encoding IL-2 linked to HPV-16 E7 antigen generate enhanced E7-specific CTL responses and antitumor activity.
Lin CT; Tsai YC; He L; Yeh CN; Chang TC; Soong YK; Monie A; Hung CF; Lai CH
Immunol Lett; 2007 Dec; 114(2):86-93. PubMed ID: 17976741
[TBL] [Abstract][Full Text] [Related]
38. Histone deacetylase inhibitor AR-42 enhances E7-specific CD8⁺ T cell-mediated antitumor immunity induced by therapeutic HPV DNA vaccination.
Lee SY; Huang Z; Kang TH; Soong RS; Knoff J; Axenfeld E; Wang C; Alvarez RD; Chen CS; Hung CF; Wu TC
J Mol Med (Berl); 2013 Oct; 91(10):1221-31. PubMed ID: 23715898
[TBL] [Abstract][Full Text] [Related]
39. Different domains of glycoprotein 96 influence HPV16 E7 DNA vaccine potency via electroporation mediated delivery in tumor mice model.
Daemi A; Bolhassani A; Rafati S; Zahedifard F; Hosseinzadeh S; Doustdari F
Immunol Lett; 2012 Dec; 148(2):117-25. PubMed ID: 23085605
[TBL] [Abstract][Full Text] [Related]
40. Induction of robust cellular immunity against HPV6 and HPV11 in mice by DNA vaccine encoding for E6/E7 antigen.
Shin TH; Pankhong P; Yan J; Khan AS; Sardesai NY; Weiner DB
Hum Vaccin Immunother; 2012 Apr; 8(4):470-8. PubMed ID: 22336879
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
